women were postmenopausal, and 1296 (84.2%) reported abnormal vaginal bleeding. Gray-scale and colour Doppler features changed with increasing grade and stage. High-risk tumours (stage 1A, grade 3 or non-endometrioid or > stage 1B) were less likely to have regular endometrial myometrial border (difference of -23%, 95% CI -27 to -18%), whilst they were larger (mean endometrial thickness; difference of +9mm, 95% CI +8 to +11mm), more frequently had non-uniform echogenicity (difference of -10%, 95% CI -15 to -5%), the multiple, multifocal vessel pattern (difference of +21%, 95% CI +16 to +26%), and a moderate or high colour score (difference of +22%, 95% CI +18 to +27%), than low-risk tumours. Conclusions: Gray-scale and colour Doppler ultrasound features of endometrial tumours vary by grade and stage. This knowledge may improve preoperative ultrasound discrimination between low and high-risk cancer.
Objectives: High rate (15-29%) of complete hydatidiform mole (CHM) patients progress to persistent gestational trophoblastic neoplasia (GTN). The importance of prognostic factor identification in CHM was the subgroup of patients in different classes according to the risk of the invasive progress. But there are few predictors of the clinical course of CHM. In 25th ISUOG congress, we reported an ultrasound-based mathematical model for predicting GTN from CHM, which was Log (p(malignancy=1)/p(normal=0)) = -2.23 + 4.39e-7 × hCG + 4.11e-5×preoperational uterus volume + 2.30×abundant blood in postoperational uterus. The further study has been done on the last two years to test it on prospective patients. Methods: 102 CHM patients were recruited in the testing mode from September 2012 to March 2015. They underwent ultrasound exams before evacuation and 7 days after evacuation. The predictor mode value was calculated and malignance was predicted if the value was more than 0.146. The predicting results were compared with the 2-year follow-up outcomes. Results: The mode predicted 29 cases of malignancies and 73 normal cases. During the 2-year monitoring, 28 cases developed to GTN and 74 cases spontaneously regressed. Evaluated on the test set, the performance was 82.8% positive predictive value, 94.5% negative predictive value, 85.7% sensitivity, 92.0% specificity, 10.71 positive likelihood ratio, 0.16 negative likelihood ratio and 91.2% accuracy.
Conclusions:
The ultrasound-based mathematical model for predicting GTN from CHM was validated in the test set. The model on the basis of pre-and post-evacuation ultrasound and serum hCG has the potential value to be an easy, cheap and safe method to accurately predict results of CHM.
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Preoperative assessment of the extent of disease in ovarian cancer: comparative study of ultrasound and CT scan Objectives: To compare the diagnostic performance of ultrasound and CT scan in the preoperative assessment of disease spread in ovarian cancer patients. Methods: Prospective study including 90 patients (mean age 56.2 years, range: 15-79 years) with ultrasound diagnosis of adnexal mass suspected of malignancy. In all cases transvaginal and transabdominal ultrasound were performed to assess the extent of the disease. The exploration was systematic and analysing 12 anatomic areas. The patients were submitted to abdomino-pelvic CT scan for evaluating the same anatomical areas. All patients underwent surgery and eventual staging and/or cytoreductive surgery. The surgical and pathological findings were considered as ''Gold standard". Sensitivity and specificity of ultrasound and CT were calculated for the different anatomical areas and were compared using the Mc Nemar Test. Results: Of the total of 90 patients, 43 cases were excluded (7 tumours were histologically benign, 13 were borderline tumours, 3 patients did not undergo surgery and 19 patients to whom CT was not finally performed). Tumoural stages were: I: 18; II: 10; III: 23; IV: 6. Table 1 shows the sensitivity and specificity for both techniques. Conclusions: Detailed ultrasound offers similar diagnostic performance than CT scan for assessing tumour spread in women with ovarian cancer. 
OC14.03:

